ProCE Banner Activity

CE / CME

Current Controversies in Viral Hepatitis

Multimedia

Led by Paul Martin, MD, a panel of experts discusses their management approach to several controversial clinical scenarios, including whether to treat patients with immune-tolerant HBV infection, whether all patients receiving suppressive TDF for the treatment of HBV infection should be switched to TAF, if it is reasonable to discontinue oral therapy in select patients with HBeAg-negative HBV infection who do not have cirrhosis, and whether increased engagement by liver disease specialists will be needed to reach HCV elimination goals by 2030.

Pharmacists : 1.25 contact {hours} ({0.125} CEUs)

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: July 06, 2018

Expiration: July 05, 2019

No longer available for credit.

Share

Faculty

Norah Terrault

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Paul Martin

Paul Martin, MD

Professor of Medicine
Associate Director,
 Division of Liver Disease
Mount Sinai School of Medicine
New York, New York

Christian B. Ramers

Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grants provided by

AbbVie

Gilead

Janssen

Merck & Co., Inc.

ViiV Healthcare

Target Audience

This program is intended for infectious diseases clinicians, hepatologists, gastroenterologists, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with viral hepatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select guideline-recommended, evidence-based management strategies for patients with different phases of chronic HBV infection
  • Apply key guidelines and study data to ensure appropriate, individualized management for diverse patient populations with chronic HBV infection, based on individual patient factors
  • Implement practical strategies to optimize outcomes in patients receiving therapy for chronic HBV infection

Disclosure

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director Disclosure

Program Director

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from ADMA Biologics, Dova, and Merck and funding for research support from AbbVie, ADMA Biologics, Allergan, Bristol-Myers Squibb, Eisai, Gilead Sciences, Grifols, Lion TCR, Merck, and Perspectum Diagnostics.

Faculty Disclosure

Primary Author

Paul Martin, MD

Professor of Medicine
Associate Director,
 Division of Liver Disease
Mount Sinai School of Medicine
New York, New York

Paul Martin, MD, has disclosed that he has received consulting fees from AbbVie and Merck and funds for research support from AbbVie, Gilead Sciences, and Merck.

Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Christian B. Ramers, MD, MPH, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, and Gilead Sciences; fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from AbbVie, Gilead Sciences, Janssen, and Merck; and funds for research support from Gilead Sciences.

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD, FAASLD, AGAF, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and Merck and funds for research support from AbbVie.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-18-086-H01-P. This program is designated for up to 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 06, 2018, through July 05, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in viral hepatitis management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.